Know Cancer

or
forgot password

Myeloid Suppressors in Inflammation


N/A
18 Years
60 Years
Not Enrolling
Both
Asthma

Thank you

Trial Information

Myeloid Suppressors in Inflammation

Inclusion Criteria


Inclusion

1. Ages eligible for study: 18 to 60 years

2. Genders eligible for study: male and female

3. Signed and dated written informed consent is obtained prior to study blood draw.

4. Subjects being actively treated for chronic moderate to severe asthma based on
National Heart Lung and Blood Institute guidelines (figure 1). Subjects must carry
the diagnosis of asthma (made by a physician) for a minimum of six months.

5. Subjects within the first seven days of an acute asthma exacerbation, as determined
by the referring physician.

6. Able to give informed consent.

Exclusion Criteria:

1. Use of systemic corticosteroids within the previous two weeks.

2. Pregnant and/or lactating females.

3. Current tobacco use.

4. Severe psychiatric illness.

5. Current illicit substance abuse or dependence and/or abuse of alcohol.

6. Current use of anti-microbial medications.

7. Primary or secondary immunodeficiency.

8. Any clinically significant uncontrolled medical condition that would put the
patient's safety at risk.

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

To identify and characterize specific cell types (human dendritic cells, myeloid-derived suppressor cells and T lymphocytes) that are present in acute and chronic asthma.

Outcome Time Frame:

one year from start of study

Safety Issue:

No

Principal Investigator

Richard Lockey, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

USF Asthma, Allergy and Immunology CRU

Authority:

United States: Food and Drug Administration

Study ID:

MYELOID

NCT ID:

NCT01224223

Start Date:

October 2010

Completion Date:

January 2012

Related Keywords:

  • Asthma
  • asthma
  • Asthma
  • Inflammation

Name

Location

USF Asthma, Allergy and Immunology CRUTampa, Florida  33613